Systematic review of atomoxetine data in childhood and adolescent attention-deficit hyperactivity disorder 2009–2011: Focus on clinical efficacy and safety
Open accessThe DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
Background: Clinicians obtain critical prescribing knowledge from clinical papers and review articles. This is the first published systematic review of clinical atomoxetine data covering 2009–2011. Objective: We aim to update clinicians on current clinical atomoxetine data with specific reference to time of onset of efficacy and maximal efficacy. These data may allow critical analysis of comparative efficacy between atomoxetine and stimulant medications. Methods: A formal systematic review of atomoxetine data from January 2009–June 2011 was conducted. The search term used was “atomoxetine” in the English language. The search yielded 747 citations from which 106 are clinical data. This paper includes clinical efficacy and safety data and excludes quality-of-life and review papers. Results: Atomoxetine has an onset of action within 4 weeks (possibly within 1 week in subsequent responders) but requires at least 12 weeks for full response to be demonstrated. Treatment-naïve cohorts (6–12 weeks) report effect sizes of 0.6–1.3. Using minimum 6-week clinical trial criteria, atomoxetine may demonstrate similar efficacy to methylphenidate comparing reduction in core ADHD symptoms in meta-analysis, although the diversity of the data makes interpretation complex. From epidemiological databases, cardiovascular and suicide-related events were similar to those seen in patients taking methylphenidate. Conclusions: Incremental response time to atomoxetine should be considered in the design of future comparative efficacy trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The worldwide prevalence of ADHD: a systematic review and metaregression analysis
Polanczyk, G., de Lima, M. S., Horta, B. L., Biederman, J., & Rohde, L. A. (2007) · American Journal of Psychiatry · doi:10.1176/ajp.2007.164.6.942 · Cited by 5,346
ADHD Drugs and Serious Cardiovascular Events in Children and Young Adults
Cooper, W. O., Habel, L. A., Sox, C. M., Chan, K. A., Arbogast, P. G., Cheetham, T. C., Murray, K. T., Quinn, V. P., Stein, C. M., Callahan, S. T., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1110212 · Cited by 411
Newcorn, J. H., Kratochvil, C. J., Allen, A. J., Casat, C. D., Ruff, D. D., Moore, R. J., Michelson, D., & Atomoxetine/Methylphenidate Comparative Study Group (2008) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2007.05091676 · Cited by 336 · cited 2×
“Thus, some of the earlier studies cited to support superior efficacy of MPH over ATX and being only of 3–6 weeks duration may not have been long enough to show the maximal ATX efficacy (Kemner et al., 2005; Newcorn et al., 2008).”
BackgroundResultBloch, M. H., Panza, K. E., Landeros-Weisenberger, A., & Leckman, J. F. (2009) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/chi.0b013e3181b26e9f · Cited by 270
Attention-deficit hyperactivity disorder: treatment discontinuation in adolescents and young adults
McCarthy, S., Asherson, P., Coghill, D., Hollis, C., Murray, M., Potts, L., Sayal, K., de Soysa, R., Taylor, E., Williams, T., et al. (2009) · British Journal of Psychiatry · doi:10.1192/bjp.bp.107.045245 · Cited by 215
Review: Mortality in schizophrenia: a measurable clinical endpoint
Bushe, C. J., Taylor, M., & Haukka, J. (2010) · Journal of Psychopharmacology · doi:10.1177/1359786810382468 · Cited by 185 · cited 1×
“Attention has also been focusing more on pragmatic endpoints in ADHD in parallel with what has been taking place in psychiatry worldwide (Bushe et al., 2010).”
BackgroundSelf-citationCardiovascular Events and Death in Children Exposed and Unexposed to ADHD Agents
Schelleman, H., Bilker, W. B., Strom, B. L., Kimmel, S. E., Newcomb, C., Guevara, J. P., Daniel, G. W., Cziraky, M. J., & Hennessy, S. (2011) · Pediatrics · doi:10.1542/peds.2010-3371 · Cited by 159
Meta-Analysis of Suicide-Related Behavior Events in Patients Treated With Atomoxetine
BANGS, M. E., TAUSCHER-WISNIEWSKI, S., POLZER, J., ZHANG, S., ACHARYA, N., DESAIAH, D., TRZEPACZ, P. T., & ALLEN, A. J. (2008) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/chi.0b013e31815d88b2 · Cited by 152
McCarthy, S., Cranswick, N., Potts, L., Taylor, E., & Wong, I. C. K. (2009) · Drug Safety · doi:10.2165/11317630-000000000-00000 · Cited by 128
Kemner, J. E., Starr, H. L., Ciccone, P. E., Hooper-Wood, C. G., & Crockett, R. S. (2005) · Advances in Therapy · doi:10.1007/bf02849870 · Cited by 99 · cited 1×
“Thus, some of the earlier studies cited to support superior efficacy of MPH over ATX and being only of 3–6 weeks duration may not have been long enough to show the maximal ATX efficacy (Kemner et al., 2005; Newcorn et al., 2008).”
Result
Cited by
Attention deficit hyperactivity disorder
Thapar, A., & Cooper, M. (2016) · The Lancet · doi:10.1016/s0140-6736(15)00238-x · Cited by 1,043
Thapar, A., Cooper, M., & Rutter, M. (2017) · The Lancet Psychiatry · doi:10.1016/s2215-0366(16)30376-5 · Cited by 903
Chen, Q., Sjolander, A., Runeson, B., D'Onofrio, B. M., Lichtenstein, P., & Larsson, H. (2014) · BMJ · doi:10.1136/bmj.g3769 · Cited by 170
Reed, V. A., Buitelaar, J. K., Anand, E., Day, K. A., Treuer, T., Upadhyaya, H. P., Coghill, D. R., Kryzhanovskaya, L. A., & Savill, N. C. (2016) · CNS Drugs · doi:10.1007/s40263-016-0349-0 · Cited by 113
“of atomoxetine data from 2009 to 2011 has previously been published [22], and efficacy and safety data for atomoxe-”
BackgroundSelf-citationLilja, M. M., Sandblom, E., Lichtenstein, P., Serlachius, E., Hellner, C., Bhagia, J., & Halldner, L. (2022) · Journal of Neurodevelopmental Disorders · doi:10.1186/s11689-022-09424-2 · Cited by 14
Metadata
- Authors
- Bushe, C. J., & Savill, N. C.
- Venue
- Journal of Psychopharmacology
- Publisher
- SAGE Publications
- Published
- 2013-02-25
- Volume
- 28
- Issue
- 3
- Pages
- 204-211
- ISSN
- 0269-8811 (ISSN-L)
- 1461-7285
- OpenAlex
- W2141784450
- Cited by
- 72
- References
- 19
- FWCI
- 1.75
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Systematic review of atomoxetine data in childhood and adolescent attention-deficit hyperactivity disorder 2009–2011: Focus on clinical efficacy and safety. https://app.cochat.ai/papers/10.1177/0269881113478475
- The paper
- Bushe, C. J., & Savill, N. C. (2014). Systematic review of atomoxetine data in childhood and adolescent attention-deficit hyperactivity disorder 2009–2011: Focus on clinical efficacy and safety. Journal of Psychopharmacology. https://doi.org/10.1177/0269881113478475
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.